Search

everythinglearnresearchcommunity

for

Search:↓

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The user shared their 11-month hair regrowth journey using 0.83mg finasteride, Minoxidil twice daily, random derma rolling, and occasional Ketoconazole showers. They reported significant improvement, moving from a Norwood scale of 5.5 to around 2.5-3, and encouraged consistency for results.

The user shared their hair regrowth progress using finasteride, minoxidil, microneedling, and tretinoin cream, noting inconsistency in their routine. They plan to be more consistent with treatments in the future.

The user has been using minoxidil, dermarolling, and nizoral shampoo for hair regrowth but hasn't fully restored their hairline. They are considering adding finasteride to their regimen.

The user is using dutasteride, oral and topical minoxidil, Nutrafol, Revita shampoo, ketoconazole shampoo, and a derma roller for hair regrowth. They plan to get a hair transplant next year.

Finasteride may be sufficient for diffuse thinning, but dutasteride is generally considered more effective, with a higher chance of hair growth. Adding oral minoxidil can improve results, though some users report side effects.

A user experienced significant hair regrowth after 6 months using 1mg Finasteride and Oral Minoxidil, along with pumpkin seed oil, biotin, and collagen supplements, and is considering starting PRP. Another user has not seen results despite using a combination of treatments including finasteride, minoxidil, RU58841, pyrithione zinc, topical dutasteride, ketoconazole, and microneedling.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

The user is using a comprehensive hair loss prevention regimen including Dutasteride, RU58841, topical treatments, red light therapy, microneedling, and supplements like Nutrafol, while avoiding Minoxidil. They also supplement with vitamin D and zinc and plan to start testosterone replacement therapy (TRT) in January.

The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.